UroGen Pharma will invest up to $7 million in IntraGel while securing an option on TumoCure and potential rights to three additional SRGel oncology programmes.
UroGen files UGN-103 with the FDA after a 77.8% Phase 3 complete response rate as its bladder cancer franchise gains commercial momentum.
UroGen Pharma Ltd. (Nasdaq: URGN) has received U.S. Food and Drug Administration clearance of its Investigational New Drug application for UGN-501, an investigational next-generation oncolytic virus for non-muscle invasive bladder cancer. The clearance enables the urothelial cancer-focused biotechnology company to begin a planned Phase 1 trial of local intravesical administration, with patient enrollment expected to
Find out how UroGen Pharma’s UGN-501 could test oncolytic virus therapy for recurrent non-muscle invasive bladder cancer.